> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Ascentage Pharma Orphan Status for Follicular Lymphoma
- URL: https://www.fdaweb.com/ascentage-pharma-orphan-status-for-follicular-lymphoma/
- Published: 2021-01-29T12:00:00.000Z
- Updated: 2026-09-14T16:44:38.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5148560

FDA has granted Ascentage Pharma an orphan drug designation for its novel Bcl-2 inhibitor, APG-2575, for treating patients with follicular lymphoma (FL). The company says FL is a heterogeneous disease and the second most common subtype of non-Hodgkin lymphoma (NHL) among adult patients in the U.S. APG-2575 is described as a novel, orally administered small-molecule Bcl-2 selective inhibitor. It is designed to treat hematologic malignancies and solid tumors by selectively blocking antiapoptotic protein Bcl-2 to restore the normal apoptosis process in cancer cells.